The tweet was deleted by the author.
But we saved everything 🙂.
Pstream Bio stock rises 2.6% after Q2 results and pipeline update
Upstream Bio reported second quarter 2026 financial results. The stock is up 2.6% on the day at $7.44.
Highlights
- Upstream Bio reports continued progress for verekitug in severe asthma, chronic rhinosinusitis with nasal polyps and COPD, with Phase 3 trials for two indications planned for early 2027.
- Twenty-eight of 33 analysts covering Upstream Bio stock rate it a buy, with a median price target of $39.5.
- Upstream Bio stock is up 2.6% on the day at $7.44.
Upstream Bio reported its second quarter 2026 financial results. The company also announced ongoing progress for verekitug in three indications: severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). Upstream Bio remains on track to begin Phase 3 trials for severe asthma and CRSwNP in the first quarter of 2027.
View post on X Loading...
Range resistance in focus as stock gaps up on mixed momentum
Upstream Bio stock opened the session with a gap up from $7.25 to $7.37. The price is positioned below the MA-200, but above the MA-20 and MA-50, reflecting a split daily structure. RSI at 62.1 is nearing overbought territory, an early indication that the recent advance may be getting stretched. The nearest resistance is the weekly high at $7.62, which will be an important area for buyers to overcome.
Odds tilt slightly to the upside as traders await $7.62 breakout
To determine whether the recent revenue development is being absorbed into the price, traders should watch for a close above $7.62 as evidence that buyers are showing follow-through. In the latest session, the stock jumped at the open, climbing from a previous close of $7.25 to $7.37 as trading began. While the past week saw a sharp move higher without a sustained trend, from here the five-day outlook gives a 52% probability of upside and a 48% probability of downside, with an expected trading range between $6.89 and $7.98. A drop below $7.05 would indicate the move is being rejected. On the weekly chart the longer-term picture stays negative.
Previously it was reported that Upstream Bio planned to initiate Phase 3 clinical trials for verekitug targeting severe asthma and CRSwNP in early 2027. With technicals showing the stock nearing a key resistance at $7.62, traders should monitor for a confirmed breakout above this level as an indication of sustained upward momentum.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
